Skip to main content

Advertisement

Table 3 Association between irinotecan sensitivity and clinical characteristics

From: A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

Characteristic Irinotecan inhibition rate Irinotecan inhibition rate
  mean (95% CI) mean (95% CI)
  Training set (N = 100) Independent testing set (N = 75)
Age, y median (range)   
 ≥ 63 42% (36–47%) 44% (31–57%)
 < 63 45% (39–51%) 44% (34–54%)
Sex   
 Male 43% (38–47%) 42% (33–51%)
 Female 45% (36–55%) 50% (31–68%)
Tumor Site   
 Distal stomach 42% (35–49%) 44% (28–60%)
 Proximal stomach 44% (38–51%) 47% (35–58%)
 Whole stomach 43% (35–51%) 37% (16–59%)
Stage   
 I 34% (21–47%) 36% (3–70%)
 II 49% (40–57%) 50% (31–68%)
 III 43% (38–48%) 44% (34–54%)
 IV 33% 34%
Histological grade   
 2 41% (33–49%) 44% (21–68%)
 3 42% (36–48%) 39% (27–51%)
 Mixed 1–2 54% 58%
 Mixed 2–3 46% (38–54%) 49% (35–62%)
Lymph node metastasis   
 No 42% (33–51%) 46% (27–65%)
 Yes 44% (39–48%) 44% (34–53%)
Signature index   
 > 0.43 57% (52–63%) ** 65% (61–70%) **
 ≤ 0.43 31% (27–36%) 22% (17–28%)
  1. ** P < 0.001.